drug
deliveri
system
dd
studi
mean
improv
medic
sinc
magic
bullet
concept
describ
hundr
year
ago
paul
ehrlich
scientist
medicin
pharmaceut
materi
scienc
tri
discov
creat
sophist
drug
target
specif
molecul
cell
tissu
dd
one
key
technolog
deliv
drug
target
site
bodi
numer
type
nanomateri
includ
liposom
lp
polym
investig
dd
use
clinic
set
nanomateri
contain
drug
molecul
encapsul
physic
adsorpt
chemic
linkag
deliv
target
nanoformul
drug
avoid
renal
excret
allow
prolong
circul
bodi
contribut
improv
bioavail
moreov
nanos
materi
passiv
accumul
tumor
tissu
site
inflamm
site
via
enhanc
permeabl
retent
epr
effect
nanoformul
contain
target
moieti
recogn
specif
target
molecul
bodi
accumul
specif
site
bodi
howev
research
caution
current
dd
technolog
remain
far
true
magic
bullet
one
metaanalysi
reveal
total
nanoparticl
np
administ
vivo
accumul
target
tumor
tissu
almost
drug
accumul
nontarget
tissu
clear
bodi
furthermor
clinic
set
human
tumor
sometim
exhibit
epr
effect
current
dd
studi
sum
mani
paper
drug
situat
reflect
complex
nanocarri
compar
parent
drug
furthermor
despit
contrari
expect
activ
target
dd
slightli
improv
pharmacokinet
accumul
drug
target
tissu
compar
nontarget
formul
cytoplasm
deliveri
anoth
issu
dd
deliveri
nucleic
acid
medicin
plasmid
dna
short
interf
rna
sirna
microrna
mirna
drug
molecul
deliv
nucleu
cytoplasm
target
cell
exert
biolog
function
nucleic
acid
inher
penetr
cell
membran
intracellularli
deliv
via
dd
cellular
uptak
drug
endosom
escap
ratelimit
step
even
cuttingedg
lipid
np
platform
cargo
sirna
escap
endosom
cytoplasm
elicit
rna
interfer
synthet
nanocarri
remain
hamper
issu
virus
natur
evolv
deliv
genet
materi
dna
rna
genom
host
cell
elabor
ration
fashion
entri
host
bodi
virus
evad
host
defens
reach
specif
organ
cell
virus
taken
cell
traffic
intracellular
space
releas
genom
replic
virus
exploit
protein
lipid
compon
surmount
cellular
barrier
dd
technolog
learn
great
deal
virus
bioinspir
materi
investig
wide
varieti
applic
materi
scienc
biomed
research
materi
uniqu
characterist
function
compar
humandesign
materi
recombin
virus
alreadi
util
deliveri
system
gene
therapi
howev
natur
virusbas
dd
inher
safeti
issu
includ
immunogen
insert
genet
inform
viru
host
genom
sever
clinic
trial
fail
due
safeti
problem
viral
vector
ideal
infect
machineri
transplant
virus
artifici
np
avoid
intrins
unexpect
toxic
virus
review
summar
machineri
oper
earli
viral
infect
process
hope
util
virusinspir
dd
focu
evas
reticuloendotheli
system
re
tissu
tropism
cell
entri
endosom
escap
current
approach
develop
virusinspir
ddss
describ
final
section
review
summar
strategi
develop
virusinspir
dd
mimick
infect
machineri
hepat
b
viru
hbv
virus
varieti
size
shape
determin
abil
evad
host
immun
respons
gener
virus
divid
two
categori
shape
spheric
virus
includ
human
immunodefici
viru
influenza
viru
ifv
hbv
adeno
associ
viru
nonspher
virus
rodlik
ellipt
shape
eg
tobacco
mosaic
viru
tmv
virus
spheric
although
differ
subvir
structur
present
exampl
hbv
specif
infect
human
liver
cell
virion
approxim
nmsize
spheric
structur
term
dane
particl
subvir
particl
hbv
found
patient
plasma
interestingli
differ
dane
particl
anoth
particl
spheric
approxim
diamet
nm
still
anoth
particl
filament
lack
genet
materi
biolog
function
particl
unclear
recent
postul
subvir
particl
may
decoy
neutral
antibodi
produc
hbv
virion
biodistribut
especi
circul
time
bloodstream
evalu
concern
plant
viru
tmv
rodshap
nm
length
nm
diamet
lower
viral
protein
concentr
tmv
form
spheric
structur
mice
rodshap
structur
longer
circul
time
bloodstream
clear
less
rapidli
tissu
sphericalshap
structur
indic
viral
shape
play
import
role
biodistribut
howev
effect
natur
virus
shape
immun
evas
difficult
studi
overcom
barrier
differ
method
evalu
viral
behavior
bloodstream
includ
virusmimick
gold
np
model
intent
model
simul
featur
could
influenc
immun
evas
exampl
rodshap
gold
np
modifi
poli
ethylen
glycol
peg
accumul
liver
lesser
extent
circul
longer
blood
compar
spheric
np
size
viral
particl
also
import
host
evas
monocyt
macrophag
phagocyt
cell
respons
clearanc
virus
effici
engulf
particl
sizedepend
manner
especi
particl
micromet
rang
inde
diamet
viru
influenc
cellular
uptak
pathway
larg
virus
mimiviru
nm
diamet
taken
macrophag
via
phagocytosi
smaller
virus
tend
intern
cell
via
clathrinmedi
endocytosi
although
immun
evas
mechan
viru
differ
size
may
one
key
factor
determin
immun
evas
abil
virus
surfac
charg
hydrophob
viral
particl
also
import
immun
escap
hydrophob
particl
like
taken
cell
hydrophil
nonion
particl
posit
charg
particl
longer
circulatori
time
neg
charg
particl
indic
surfac
charg
influenc
circul
time
virus
surfac
charg
virion
depend
surround
environ
accord
isoelectr
point
pi
viral
protein
govern
ph
environ
surfac
charg
viral
protein
variabl
even
neg
charg
posit
charg
among
virus
investig
virus
less
pi
virus
possess
pi
higher
rare
found
suggest
major
virus
show
neg
charg
surfac
physiolog
condit
virus
neg
charg
glycan
may
prevent
opson
lead
escap
phagocytosi
virus
use
mani
complic
mechan
evad
host
immun
system
viral
proteinmedi
manner
strategi
evas
mechan
includ
interfer
antigen
present
major
histocompat
complex
mhc
molecul
evas
cytotox
lymphocyt
ctl
antigen
variat
ctl
recogn
viral
antigen
mhc
class
activ
antivir
immun
system
virus
util
uniqu
activ
evas
mechan
achiev
prolong
circul
time
bloodstream
exampl
glycoprotein
epsteinbarr
viru
interact
mhcii
molecul
hinder
antigen
present
tcell
case
envelop
protein
bind
molecul
inhibit
interact
mhcii
envelop
protein
hepat
c
viru
hcv
bind
prevent
natur
killer
nk
cellmedi
lysi
cytokin
releas
virus
also
shield
envelop
layer
consist
highli
glycosyl
protein
barrier
reduc
recognit
immun
system
strategi
oper
earli
infect
host
cell
follow
virion
secret
lipid
protein
deriv
host
cell
util
strategi
oper
evas
complement
system
major
nonspecif
host
defens
mechan
cowpox
viru
equip
inhibitor
complement
ie
inflamm
modulatori
protein
inhibit
product
infect
virus
includ
human
cytomegaloviru
vaccinia
viru
util
similar
strategi
incorpor
host
protein
envelop
result
protect
complement
lysi
complement
system
consist
classic
altern
lectin
pathway
also
import
immun
respons
recogn
invad
pathogen
activ
antivir
activ
howev
virus
evad
complement
system
exampl
envelop
protein
west
nile
viru
bind
factor
h
regul
altern
pathway
complement
activ
bloodstream
cell
surfac
case
amino
acid
sequenc
indic
interact
factor
h
immedi
dissoci
envelop
complex
virus
may
becom
invis
host
genet
mutat
hbv
hcv
harbor
specif
mutat
envelop
protein
stealth
mutant
mutant
virus
escap
host
immun
reaction
due
modif
viral
protein
epitop
recogn
host
b
cell
although
pegyl
nanocarri
approv
unit
state
food
drug
administr
fda
nanomedicin
vehicl
repetit
administr
pegyl
nanocarri
may
elicit
antipeg
antibodi
lead
rapid
clearanc
pegyl
nanocarri
bodi
aforement
viral
system
shall
contribut
develop
stealth
ddss
novel
strategi
evad
host
defens
mechan
heparan
sulfat
proteoglycan
hspg
glycoprotein
locat
close
proxim
cell
surfac
extracellular
matrix
consist
core
protein
coval
attach
heparan
sulfat
chain
mani
type
hspg
found
cellular
membran
extracellular
matrix
secretori
vesicl
membranebound
hspg
contain
syndecan
glycosylphosphatidylinositolanchor
proteoglycan
glypican
hspg
extracellular
matrix
contain
agrin
perlecan
type
xviii
collagen
hspg
secretori
vesicl
contain
serglycin
interact
hspg
play
mani
import
role
biolog
function
cell
migrat
cell
prolifer
cell
recognit
endocytosi
earli
infect
virus
hspg
play
initi
lowaffin
receptor
respons
cell
recognit
may
also
trigger
conform
chang
viru
envelop
protein
mani
virus
interact
hspg
earli
infect
step
dengu
viru
adenoassoci
virus
herp
simplex
hbv
sialic
acid
deriv
neuramin
acid
ubiquit
express
higher
vertebr
firstli
identifi
lowaffin
viru
receptor
lead
cell
entri
virus
ifv
parainfluenza
viru
adenoviru
adv
coronaviru
case
ifv
hemagglutinin
ha
protein
bind
sialic
acid
initi
infect
induc
fusion
viral
cellular
membran
besid
lowaffin
receptor
includ
hspg
sialic
acid
viru
gener
requir
specif
highaffin
receptor
determin
tissu
tropism
virus
util
multipl
highaffin
receptor
success
infect
exampl
human
hepatotrop
viru
hcv
envelop
rna
viru
genom
belong
hepaciviru
genu
flavivirida
famili
cell
entri
hcv
occur
follow
hcv
interact
lowdensitylipoprotein
receptor
hspg
surfac
human
hepatocyt
subsequ
interact
scaveng
receptor
class
b
member
expos
domain
locat
hcv
glycoprotein
hcv
bind
tight
junction
interact
claudin
induc
clathrinmedi
endocytosi
occludin
niemannpick
shown
essenti
receptor
precis
role
infect
process
current
unknown
clathrinmedi
endocytosi
extens
studi
best
understood
endocytosi
pathway
includ
format
clathrinco
pit
vesicl
cargo
recruit
vesicl
fission
clathrinmedi
endocytosi
occur
cell
type
necessari
turnov
membran
protein
lipid
uptak
nutrient
virus
exploit
clathrinmedi
endocytosi
process
gain
entri
host
cell
shown
semliki
forest
viru
sfv
vesicular
stomat
viru
vsv
hcv
adv
dengu
viru
clathrinmedi
endocytosi
carri
cargo
molecul
plasma
membran
earli
endosom
within
min
clathrinmedi
endocytosi
virus
gener
quick
case
dengu
viru
viru
particl
firstli
move
along
plasma
membran
minut
associ
clathrincontain
domain
next
viru
deliv
late
endosom
within
min
cell
entri
fuse
endosom
membran
within
min
follow
clathrinmedi
endocytosi
viru
cargo
transport
earli
endosom
within
sever
minut
help
protein
virus
immedi
move
late
endosom
switch
rab
subset
start
fuse
endosom
membran
acid
condit
within
sever
minut
caveolaedepend
endocytosi
begin
format
endocyt
vesicl
contain
cholesterol
lipid
raft
cell
entri
cargo
transfer
earli
endosom
late
endosom
endoplasm
reticulum
instanc
use
pathway
bind
glycosphingolipid
receptor
macropinocytosi
actindepend
endocyt
event
lead
intern
cargo
larg
vesicl
activ
actin
microfila
connect
plasma
membran
induc
ruffl
plasma
membran
lead
macropinocytosi
vaccinia
viru
adv
viru
famili
util
micropinocytosi
intern
viru
particl
first
induc
actinmedi
membran
ruffl
bleb
larg
vesicl
call
macropinosom
form
plasma
membran
macropinosom
intern
virus
transloc
virus
cytoplasm
mediat
limit
membran
macropinosom
membran
fusion
major
strategi
endosom
escap
envelop
viru
uncoat
lead
releas
viral
compon
includ
viral
genom
capsid
polymeras
cytoplasm
gener
fusogen
domain
envelop
protein
respons
process
acid
condit
late
endosom
fusion
protein
undergo
conform
chang
lead
insert
hydrophob
fusogen
domain
endosom
membran
form
dehydr
interfac
hemifus
stalk
case
ifv
ha
protein
undergo
conform
chang
proton
acid
ph
lead
fusion
peptid
expos
helic
structur
result
fusion
viral
endosom
membran
membran
fusion
mechan
found
viral
envelop
protein
includ
sfv
protein
protein
although
low
ph
import
structur
chang
viral
protein
virus
differ
suitabl
condit
exampl
sfv
vsv
fuse
earli
endosom
membran
rel
high
ph
ph
wherea
ifv
typic
fuse
late
endosom
membran
lower
ph
ph
membran
pore
format
endosom
anoth
strategi
effici
endosom
escap
virus
especi
nonenvelop
virus
two
model
propos
form
pore
lipid
bilay
barrelstav
pore
toroid
channel
barrelstav
pore
model
peptid
reorient
becom
stave
collect
form
barrelshap
cluster
perpendicularli
orient
manner
plane
lipid
bilay
result
format
pore
toroid
channel
model
peptid
aggreg
enter
membran
perpendicular
orient
curv
inward
form
pore
line
peptid
case
adv
penton
base
protein
hydrophob
viral
protein
respons
pore
format
acid
environ
rhinoviru
polioviru
coxsackieviru
also
involv
strategi
pore
format
tat
protein
power
transcript
factor
integr
genom
util
virusinspir
nanomedicin
applic
enhanc
endosom
releas
posit
charg
arg
ly
residu
tat
protein
interact
neg
charg
membran
lead
lipid
membran
penetr
facilit
gene
drug
deliveri
via
membran
destabil
peptid
human
papillomaviru
peptid
also
exhibit
membranedestabil
activ
acid
condit
simplest
way
endow
synthet
nanocarri
virusderiv
infect
machineri
conjug
viral
function
compon
aforement
infect
machineri
involv
tropism
cell
entri
endosom
escap
mainli
mediat
viral
protein
viru
tropism
could
simpli
transplant
synthet
nanocarri
conjug
host
cell
receptorrecognit
domain
viral
protein
synthet
peptid
correspond
ntermin
region
hbv
envelop
l
protein
eg
myristoyl
peptid
interact
highaffin
hbv
receptor
sodium
taurochol
cotransport
polypeptid
ntcp
peptid
conjug
synthet
nanocarri
lp
lipoplex
complex
cation
lp
plasmid
dna
target
human
hepat
cell
specif
tropism
hbv
strictli
limit
human
hepatocyt
probabl
due
restrict
express
hbv
receptor
ntcp
hepatocyt
thu
hbvmimick
strategi
expect
highli
specif
liver
therefor
may
reduc
sideeffect
nonliv
organ
envelop
spike
g
glycoprotein
vsv
vsvg
frequent
use
enhanc
cellular
uptak
recombin
viru
sinc
vsvg
contain
fusogen
peptid
could
enhanc
membran
fusion
subsequ
cytosol
deliveri
drug
purifi
vsvg
mix
lipoplex
transfect
effici
lipoplex
strongli
enhanc
effect
mediat
fusogen
activ
vsvg
shown
loss
transfect
effici
lipoplex
fusionimpair
mutant
vsvg
similar
vsvg
ha
protein
ifv
could
enhanc
gene
transfer
protein
conjug
complex
form
plasmid
dna
transferrinconjug
polyli
transfect
effici
significantli
enhanc
thu
viral
compon
use
endow
synthet
nanocarri
function
deriv
virus
effici
drug
deliveri
virosom
complex
lp
viral
compon
anoth
type
virusinspir
nanocarri
concept
virosom
substanti
experi
lp
subunit
protein
ifv
mix
succeed
effici
transfer
plasmid
dna
vitro
vivo
use
virosom
construct
sendai
viru
virosom
modifi
target
ligand
exampl
virosom
construct
ifv
protein
modifi
fab
fragment
encapsul
anticanc
drug
doxorubicin
fabmodifi
virosom
deliv
drug
target
kill
tumor
cell
vitro
vivo
virosom
ifv
protein
use
deliveri
antigen
elicit
immun
reaction
dendrit
cell
vitro
virosom
also
effici
deliveri
platform
protein
vaccin
one
advantag
type
nanocarri
part
viral
compon
chemic
synthes
instanc
function
domain
viral
protein
synthes
short
peptid
moreov
viral
envelop
membran
substitut
convent
lp
thu
simplifi
viruslik
nanocarri
resembl
infect
machineri
parent
virus
variou
type
structur
protein
viru
known
spontan
form
vlp
viral
protein
express
exogen
cell
case
envelop
virus
viral
protein
requir
lipid
bilay
host
cell
membran
assembl
vlp
vlp
fulli
compos
viral
compon
might
function
resembl
parent
virus
date
variou
type
vlp
broad
rang
viru
studi
drug
deliveri
applic
vlp
human
papilloma
viru
util
deliveri
plasmid
dna
intramuscular
inject
papilloma
viru
vlp
plasmid
dna
mice
plasmid
dna
success
deliv
antigen
present
cell
gene
express
induc
platform
use
deliveri
dna
vaccin
elicit
function
immun
reaction
pathogen
furthermor
vlp
modifi
deliv
protein
cargo
fuse
compon
vlp
therapeut
protein
studi
engin
vlp
minor
protein
fuse
model
protein
egfp
yeast
cytosin
deaminas
incorpor
vlp
compos
major
protein
engin
vlp
could
function
deliv
encapsul
protein
cell
interestingli
vlp
may
resembl
biodistribut
parent
virus
upon
administr
host
exampl
oral
administr
rotaviru
vlp
follow
penetr
ileum
colon
vlp
interest
deliveri
drug
gastrointestin
tract
mention
vlp
fulli
resembl
infect
machineri
parent
virus
although
vlp
promis
platform
dd
vlp
may
elicit
immunoreact
human
due
immunogen
epitop
viral
protein
clinic
applic
immunogen
epitop
modifi
decreas
immunogen
vlp
research
tri
establish
novel
class
deliveri
materi
combin
viru
synthet
materi
approach
could
endow
virus
addit
function
properti
hybrid
baculoviru
cation
polym
polyethyleneimin
util
gene
deliveri
util
function
synthet
materi
virus
endow
uniqu
characterist
instanc
cowpea
chlorot
mottl
viru
fabric
temperatureswitch
polym
hybrid
nanocarri
show
temperaturedepend
assemblydisassembl
properti
indic
viru
modifi
synthet
materi
respond
environment
factor
temperatur
ph
although
strategi
promis
endow
virus
addit
function
intrins
immunogen
safeti
issu
virus
remain
structur
virus
tightli
link
biolog
function
virus
protect
genom
inner
space
virion
exogen
degrad
virion
display
surfac
protein
attach
host
cell
membran
outer
envelop
structur
interact
host
cell
membranereceptor
final
releas
inner
core
follow
deliveri
genom
host
nucleu
structur
hierarchi
might
ration
strategi
gener
synthet
deliveri
system
intracellular
drug
deliveri
structur
virus
inspir
us
construct
synthet
nanocarri
viruslik
coreshel
structur
fabric
nonvir
compon
nucleic
acid
protein
polym
lp
nucleic
acid
firstli
condens
cation
protein
polym
coat
materi
glover
et
al
succeed
gener
virusinspir
np
combin
plasmid
dna
design
protein
materi
function
dna
compact
protamin
endosom
escap
diphtheria
toxin
target
alphamelanocytestimul
hormon
protein
interact
plasmid
dna
form
diamet
np
capabl
deliv
plasmid
dna
achiev
enhanc
transfect
effici
nondivid
cell
group
establish
multifunct
envelopetyp
nanodevic
mend
use
plasmid
dna
polyli
dna
compact
lipid
shell
stearat
octaarginin
peptid
target
membran
penetr
owe
strong
cell
penetr
activ
octaarginin
mend
effici
transfer
plasmid
dna
cell
vitro
envelop
virus
capsid
virus
altern
nanocarri
harbor
virusinspir
structur
adv
one
common
virus
deliveri
foreign
gene
cell
experiment
clinic
set
adv
util
integrin
cell
surfac
cell
entri
sinc
adv
interact
integrin
repeat
rgd
argglyasp
motif
erbach
et
al
found
rgdconjug
cation
polym
polyethyleneimin
resembl
earli
infect
machineri
adv
plasmid
dna
condens
mix
polyethyleneimin
deriv
via
electrostat
interact
result
complex
exhibit
rgddepend
strong
transfect
effici
vitro
protein
nanocag
appli
virusinspir
dd
wellknown
protein
form
nanostructur
selfassembl
ferritin
heat
shock
protein
vault
protein
shown
form
protein
nanocag
nm
diamet
use
dd
applic
combin
protein
nanocag
viral
compon
may
resembl
infect
machineri
virus
murata
et
al
succeed
target
ferritin
nanocag
human
hepatocyt
fuse
hepatocytebind
peptid
deriv
hbv
viruslik
structur
made
pure
chemic
compon
interest
instanc
assembl
polym
chain
viruslik
nanostructur
consid
virusinspir
dd
nanocarri
polym
chain
contain
hydrophil
hydrophob
domain
assembl
coreshel
structur
nm
encapsul
payload
modif
target
moieti
polymer
nanoparticl
act
dd
nanocarri
approach
includ
selfassembl
microparticl
viruslik
structur
ever
et
al
report
synthet
colloid
particl
function
chemic
group
form
viruslik
microcapsul
result
suggest
pure
chemic
materi
util
virusinspir
dd
even
though
compon
complet
distinct
biomolecul
consider
proport
popul
world
suffer
hbv
infect
sinc
effect
antihbv
drug
avail
antihbv
vaccin
import
protect
infect
therefor
recombin
hbv
subvir
particl
produc
sinc
use
eukaryot
cell
immunogen
hb
vaccin
sinc
convent
hb
vaccin
compos
hbv
envelop
protein
lp
also
known
hepat
b
surfac
antigen
hbsag
vaccine
never
respond
hb
vaccin
ie
nonlowrespond
enhanc
antigen
immunogen
hb
vaccin
much
possibl
tri
express
complet
envelop
protein
l
region
particl
recombin
yeast
cell
fig
left
expect
elicit
addit
hbvneutral
antibodi
mani
attempt
made
research
synthes
l
particl
ntermin
sequenc
region
strongli
inhibit
synthesi
final
overcam
effect
ntermin
fusion
chicken
lysozymederiv
signal
peptid
succeed
overexpress
l
particl
yeast
cell
approxim
total
solubl
protein
particl
purifi
heat
affin
chromatographi
size
exclus
chromatographi
hollow
spheric
particl
approxim
nm
diamet
obtain
one
l
particl
estim
contain
l
protein
endoplasm
reticulum
membranederiv
lipid
bilay
surfac
local
region
region
portion
region
antigen
loop
agl
l
particl
shown
similar
hbv
sinc
surfac
structur
l
particl
similar
hbv
util
l
particl
hbvinspir
nanocarri
design
l
particl
bionanocapsul
bnc
fig
right
though
sever
decad
pass
identif
hbv
hb
patient
infect
mechan
hbv
larg
unknown
ntcp
see
chapter
last
identifi
essenti
highaffin
hbv
receptor
interact
ntermin
myristoyl
domain
hbv
sinc
exogen
express
ntcp
shown
confer
infect
suscept
hbv
nonsuscept
cell
express
ntcp
limit
hepatocyt
hepatotrop
hbv
could
wellexplain
exist
ntcp
hepatocyt
addit
ntcp
hspg
see
chapter
play
crucial
role
earli
infect
step
hbv
presum
one
hspg
glypican
attach
hbv
surfac
cell
entri
conserv
residu
agl
region
see
could
interact
hspg
possibl
lead
conform
chang
l
protein
facilit
bind
region
receptor
like
ntcp
describ
bnc
hbv
share
similar
outer
structur
henc
bnc
expect
enter
hepatocyt
recent
identifi
cell
entri
bnc
mediat
clathrinmedi
endocytosi
macropinocytosi
well
patientderiv
hbsag
particl
human
hepat
cell
cell
entri
speed
almost
hbv
bnc
chemic
conjug
myristoyl
group
essenti
hbv
infect
myrbnc
could
block
hbv
infect
vitro
competit
wherea
bnc
slightli
thu
myrbnc
shown
util
infect
machineri
hbv
fulli
ntcp
overexpress
human
hepat
cell
unexpectedli
observ
enhanc
cellular
uptak
myrbnc
suggest
ntcp
cell
surfac
could
contribut
bind
myrbnc
well
hbv
observ
led
us
propos
refin
model
infect
mechan
hbv
fig
surfac
human
hepat
cell
hspg
presum
glypican
may
main
lowaffin
receptor
endocytosi
hbv
upon
endosom
matur
hbv
like
bind
ntcp
releas
genom
cytoplasm
upon
membran
fusion
detail
yet
determin
await
studi
clarifi
receptor
coordin
work
hbv
receptor
np
inject
bloodstream
overcom
re
longer
circul
time
previous
demonstr
administr
singl
hbv
virion
establish
infect
hepatocyt
chimpanze
everi
case
mean
singl
hbv
virion
escap
re
like
owe
endogen
stealth
activ
hbv
describ
virus
mani
strategi
evad
immun
system
viral
protein
key
see
chapter
sinc
hbv
polymerizedalbumin
receptor
par
region
hbv
bind
polymer
human
serum
albumin
hsa
np
conjug
peptid
contain
par
phagocytosi
np
kupffer
cell
reduc
unpublish
data
thu
recruit
bloodderiv
hsa
par
domain
hbv
ie
albuminco
strategi
may
confer
evas
abil
bnc
hbv
could
escap
host
immun
reaction
introduc
mutat
envelop
protein
escap
mutant
sequenc
incorpor
l
protein
bnc
induct
antibnc
antibodi
impair
mice
upon
repetit
immun
weeksinterv
week
unpublish
data
strategi
might
applic
human
use
bnc
nanocarri
natur
occur
escap
mutant
virus
may
promis
platform
establish
stealth
nanocarri
evad
host
immun
reaction
seitz
et
al
report
dynam
structur
chang
region
hbv
occur
vitro
incub
sever
hour
incub
secret
hbv
could
bind
hspg
nform
hbv
sever
hour
hbv
becam
bind
hspg
bform
hbv
addit
nform
hbv
noninfecti
vitro
infect
experi
bform
hbv
highli
infecti
howev
vivo
infect
experi
use
mous
xenograft
model
nform
hbv
could
infect
human
liver
cell
bform
hbv
could
result
suggest
hspg
bind
necessari
infect
hbv
vitro
hspg
bind
allow
nonspecif
accumul
hbv
nontarget
tissu
prevent
liver
specif
accumul
hbv
blood
circul
hbv
may
chang
structur
nform
bform
uniqu
properti
hbv
inspir
us
establish
nanocarri
convert
stealth
form
activ
form
blood
circul
studi
regard
stealth
activ
hbv
vivo
help
gener
novel
class
stealth
nanocarri
tropism
hbv
strictli
limit
human
hepatocyt
therefor
bnc
expect
exhibit
hbvmimick
infect
machineri
human
hepatocyt
fluorophor
plasmid
encod
enhanc
green
fluoresc
protein
incorpor
electropor
bnc
deliv
human
hepat
cell
specif
vitro
intraven
inject
bnc
accumul
human
hepat
cellderiv
tumor
xenograft
mice
normal
human
liver
tissu
transplant
sever
combin
immunodefici
mice
result
indic
bnc
target
human
hepat
cell
vitro
vivo
infect
machineri
hbv
bnc
fuse
lp
form
bnclp
complex
furthermor
high
temperatur
low
ph
facilit
fusion
bnc
lp
lead
format
bncvirosom
bncvirosom
contain
doxorubicin
inject
hepat
tumorbear
xenograft
mice
growth
hepat
cellderiv
tumor
inhibit
effect
specif
strongli
suggest
bncvirosom
deliv
payload
tumor
effici
util
hbvderiv
infect
machineri
furthermor
bncvirosom
found
deliv
payload
cytoplasm
result
indic
virosom
promis
cytoplasm
nanocarri
druggen
deliveri
expand
possibl
bnc
tri
retarget
bnc
human
hepat
cellsliv
cellstissu
treatment
variou
diseas
first
part
region
l
protein
substitut
epiderm
growth
factor
egf
genet
modif
egfdisplay
bnc
target
egfroverexpress
cell
vitro
retarget
strategi
bnc
summar
previou
review
date
succeed
retarget
bnc
variou
cell
tissu
constitut
vitro
vivo
deliveri
experi
henc
bnc
could
achiev
therapeut
effect
nonhuman
liver
tissu
describ
chapter
uncoat
endosom
escap
necessari
envelop
virus
deliv
viral
genom
cytoplasm
hbv
postul
escap
endosom
membran
fusion
previous
three
domain
propos
fusogen
domain
hbv
includ
ntermin
part
region
ctermin
half
region
whole
region
nevertheless
fulli
understood
domain
respons
membran
fusion
uncoat
hbv
identifi
low
phdepend
fusogen
domain
region
use
bnc
peptidedisplay
lp
peptid
correspond
region
furthermor
mutat
analysi
fusogen
peptid
reveal
hydrophob
peptid
correl
fusogen
activ
might
crucial
lowph
depend
fusogen
activ
sinc
fusogen
activ
bnc
inhibit
preincub
antibodi
fusogen
domain
domin
region
fusogen
domain
report
previous
describ
previou
review
bnc
np
ideal
dd
nanocarri
harbor
follow
six
activ
selforgan
activ
stealth
activ
target
activ
cell
entri
activ
endosom
escap
activ
virus
evolv
transfer
genet
materi
nucleu
target
cell
vivo
thu
consid
virus
natur
occur
ideal
dd
nanocarri
wherea
artifici
dd
nanocarri
still
far
ideal
dd
nanocarri
harbor
part
six
activ
review
describ
bnc
nearli
sole
dd
nanocarri
accomplish
equip
activ
howev
move
clinic
set
would
hard
pharmaceut
compani
develop
bncbase
nanomedicin
nanomedicin
produc
least
two
good
manufactur
protocol
gmp
guidelin
biolog
chemic
thu
situat
led
us
reconstitut
np
harbor
activ
equal
nextgener
bnc
use
chemic
defin
materi
concept
nextgener
bnc
similar
nonvir
componentsbas
nanocarri
see
chapter
exampl
surfac
lp
modifi
myristoyl
peptid
target
endosom
escap
activ
peptid
stealth
activ
achiev
effici
vivo
deliveri
intracellular
traffick
hbvbnclike
manner
weight
ratio
peptid
lp
minim
drug
encapsul
rate
maxim
retarget
nextgener
bnc
ntermin
part
peptid
contain
ntcpbind
site
chang
target
molecul
eg
dna
aptam
sugar
chain
home
peptid
nanobodi
moreov
sinc
nanomicel
lipid
np
requir
membran
fusion
endosom
escap
payload
fusogen
domain
replac
peptid
membran
pore
format
membran
penetr
see
chapter
strategi
fabric
nextgener
bnc
might
produc
ideal
dd
nanocarri
could
deliv
drug
gene
vivo
effici
parent
virus
review
first
summar
infect
mechan
variou
virus
might
help
establish
novel
virusinspir
dd
nanocarri
follow
section
variou
virusinspir
nanocarri
includ
platform
bnc
introduc
accord
low
deliveri
efficaci
convent
nanocarrierbas
dd
rare
commerci
ideal
virusinspir
dd
resembl
infect
machineri
viru
compon
fulli
synthet
mention
infect
machineri
viru
substitut
short
peptid
chemic
synthes
furthermor
short
peptid
might
less
immunogen
fulllength
viral
protein
combin
virusderiv
short
peptid
synthet
nanocarri
deliveri
efficaci
dd
improv
virusinspir
strategi
may
boost
dd
nanocarri
clinic
applic
